Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation. Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee ...

Luk Fook Holdings (International) (SEHK:00590) H1 2026 Earnings Call November 27, 2025 09:30 PM ET Company Participants Joanne Ho - Head of Investor Relations Tiffany Feng - Director Kathy Chan - Executive Director and CFO Mavis Hui - Director and Equity Research Operator Ladies and gentlemen, thank you for standing by, and welcome to the Luk Fook FY 2025-2026 interim results presentation. Please also note today's event is being recorded. At this time, I'd like to turn the conference call over to Ms. Joanne ...

Luk Fook Holdings (International) (SEHK:00590) H1 2026 Earnings Call November 27, 2025 09:30 PM ET Company Participants Joanne Ho - Head of Investor Relations Tiffany Feng - Director Kathy Chan - Executive Director and CFO Mavis Hui - Director and Equity Research Operator Ladies and gentlemen, thank you for standing by, and welcome to the Luk Fook FY 2025-2026 interim results presentation. Please also note today's event is being recorded. At this time, I'd like to turn the conference call over to Ms. Joanne ...

Financial Data and Key Metrics Changes - The group's revenue increased by 25.6% to HKD 6.8 billion compared to the same period last year [3] - Operating profit margin rose by 1.6 percentage points to 11.4%, boosting operating profits by 45.4% to HKD 518 million [4] - Profit attributable to equity holders increased by 42.5% to HKD 619 million, with basic earnings per share rising by 41.9% to HKD 1.05 [4] - Overall gross margin increased by 2 percentage points to 34.7%, marking a record high for both interim and annual results [4][5] - Inventory balance grew to around HKD 12.3 billion, with inventory turnover days increasing by over 60 days year-on-year [5][6] Business Line Data and Key Metrics Changes - Retailing revenue increased by 12.8% to HKD 5.26 billion, accounting for 76.8% of total revenue [8] - Wholesale revenue rose significantly by 119.6% to HKD 1.12 billion, turning selling profit from a loss to a profit of HKD 108 million [9] - Licensing income increased by 16.6% to HKD 471 million, driven by improved sales in the mainland [9] Market Data and Key Metrics Changes - Revenue from the Hong Kong/Macau/Overseas market increased by 9.9% to HKD 3.86 billion, accounting for 56.4% of total revenue [6] - Revenue from the mainland market surged by 54.2% to HKD 2.98 billion, accounting for 43.6% of total revenue [7] - Retailing revenue in the mainland increased by 23.6% to HKD 1.5 billion, despite selling losses due to gold hedging [13] Company Strategy and Development Direction - The company has set a new three-year corporate strategy focusing on overseas market expansion, market-oriented products, and operational efficiency enhancement [17] - Plans to enter at least three additional countries and add a net of 50 overseas shops within three years [18][19] - Emphasis on product differentiation and optimizing product mix to cater to both premium and affordable luxury segments [20] Management's Comments on Operating Environment and Future Outlook - Management noted that despite geopolitical tensions and rising gold prices, the group's performance remained strong across all regions [3] - The company expects to see continued double-digit growth in simple sales for the second half of the financial year [36] - Management is optimistic about future growth and network expansion, particularly in overseas markets [45] Other Important Information - The company experienced a net decrease of 174 shops globally, including 173 Luk Fook shops and one 3DG Jewelry shop [4] - The average international gold price increased by nearly 91% year-on-year, impacting sales by weight [10] - The company has integrated ESG principles into its corporate planning and operational decision-making processes [26] Q&A Session Summary Question: Can you compare November sales momentum versus October? - Management indicated that overall simple sales growth for the mainland market exceeded 40% from October to November, with self-operated shops showing mid-teen growth and licensed shops over 40% [32] Question: What is the sales momentum by products for November? - Fixed-price jewelry products are growing faster than gold sales by weight, with gold sales by weight increasing faster in November compared to fixed-price jewelry [33][34] Question: What is the guidance for simple sales growth for the full year of FY 2026? - Management expects double-digit growth to continue in the second half, despite a higher base in the second half compared to the first [36] Question: What is the outlook for gross profit margin next year? - Management anticipates maintaining a high gross margin due to the new VAT policy and lower cost inventory, with expectations for a record high margin in the second half [39] Question: What are the drivers behind the strong performance in wholesale revenue? - The shift in strategy to include exclusive and promotional products in the wholesaling business has driven significant revenue growth [41]

BlueScope Overview - BlueScope aims for an annual EBIT uplift of approximately $500 million by 2030 through growth initiatives and investments[16] - BlueScope has returned over $3.8 billion in dividends and buy-backs since FY2017[16] - BlueScope is positioning its 1,250ha property portfolio for strategic value realization[22] - BlueScope expects $179 million net proceeds after taxes and fees from sale of 50% stake in Tata BlueScope Steel (TBSL)[20] New Zealand and Pacific Islands (NZPI) Segment - The EAF project is expected to reduce NZ Steel's Scope 1 and 2 greenhouse gas emissions by up to one million tonnes, or approximately 55%[38] - The EAF project would have indicatively improved FY2025 EBIT by approximately $80 million if operational[39] - Construction segment accounts for approximately 70% of NZPI's end-use segments[49] - COLORSTEEL sales volume has grown at a CAGR of 5% indexed at FY2016[63] Climate and Sustainability - BlueScope has a 12% intensity reduction target for steelmaking GHG emissions since FY2018[179] - BlueScope has a 30% intensity reduction target for non-steelmaking GHG emissions since FY2018[179] - BlueScope estimates projects are estimated to take steelmaking emissions intensity below 1.3 tCO2-e per tonne by 2030[184] - BlueScope has completed 192 team-based HSE risk control improvement projects in FY2025[147]

Norsk Hydro Investor Day 2025 Summary Company Overview - **Company**: Norsk Hydro (OTCPK:NHYD.Y) - **Event**: Investor Day 2025 - **Date**: November 27, 2025 - **Location**: London Key Industry Insights - **Strategic Focus**: The theme for the day was "Strategic Discipline: Securing Long-Term Value Creation" with a focus on Hydro's strategic direction towards 2030 [2][3] - **Market Conditions**: The company is navigating unpredictable market conditions influenced by geopolitical conflicts, climate change, and trade tensions, particularly in the aluminum sector [6][7][8] Financial Performance - **Return on Capital**: Hydro expects to exceed its target for return on capital employed for the year [9] - **Cost Savings**: The strategic workforce reduction is projected to yield annual savings of approximately NOK 1 billion starting in 2026 [9] - **CapEx Adjustment**: CapEx guidance was adjusted down by NOK 1.5 billion due to a slower market [10] Strategic Developments - **Recycling Capacity**: Hydro has achieved an installed post-consumer scrap capacity of 860,000 tons, meeting the lower end of its 2030 target ahead of schedule [10] - **Decarbonization Efforts**: The company anticipates a 15% reduction in CO2 emissions for the year, surpassing its 10% target [12] - **Long-term Agreements**: Hydro entered a long-term offtake agreement with NKT for 274,000 tons of Hydro REDUXA through 2033 [12] Market Dynamics - **Alumina Demand**: Steady growth in alumina demand is expected, primarily driven by new capacity in Asia, particularly India and Indonesia [13] - **Bauxite Supply Risks**: There is a concentration risk in bauxite supply, with 95% of African bauxite coming from Guinea, which poses a geopolitical risk [14] - **Aluminum Demand Drivers**: The energy transition and increased defense spending are expected to drive aluminum demand significantly [17][18] Regulatory Environment - **CBAM Impact**: The Carbon Border Adjustment Mechanism (CBAM) is expected to increase European premiums by around 40%, which could benefit Hydro if implemented effectively [22][23] - **Supply Constraints**: Supply constraints outside Europe are becoming clearer, with China's capacity cap and potential smelter closures affecting material flows [22] Operational Challenges - **Market Volatility**: The extrusion market has faced significant downturns, with demand softer than expected, leading to necessary operational consolidations [35][60] - **Recycling Margins**: Recycling margins have been under pressure, particularly in Europe, while the U.S. market remains healthier due to lower scrap prices [36] Future Outlook - **Growth Potential**: Hydro aims to capture market share in low-carbon aluminum solutions, with a focus on strategic partnerships and long-term commercial agreements [34][55] - **Investment in Technology**: Continued investments in sorting technology and recycling capabilities are expected to enhance operational efficiency and profitability [38] Conclusion - **Integrated Value Chain**: Hydro's integrated value chain from mining to recycling positions it favorably in a market increasingly focused on sustainability and low-carbon solutions [26][27] - **Commitment to Decarbonization**: The company remains committed to its decarbonization roadmap and aims to exceed its 2030 targets, reflecting a strong alignment with market demands for greener products [45][51]

Financial Performance and Targets - Hydro achieved an adjusted RoaCE of 13.5% over the last 5 years [13, 183] - The company aims to deliver NOK 6.5 billion in annual improvements by 2030 through its improvement program [188, 246] - Hydro's capital allocation targets for 2025 and 2026 are reduced to NOK 13.5 billion [249] - The company targets an adjusted net debt to adjusted EBITDA ratio well below 2.0x over the cycle, with the LTM Q3-2025 ratio at 0.7x [186] - Total shareholder distributions since 2021 amount to NOK 41.0 billion [186] Extrusion Business - Hydro Extrusions is targeting an EBITDA uplift of NOK 8.0 - 10.0 billion by 2030 [68] - The company intends to reduce extrusion capacity by approximately 80 kt annually in Europe [134] - Hydro Building Systems experienced a 54% increase in EBITDA YTD 2025 in the Middle East [159] Recycling Business - The company estimates EUR 9 million out of EUR 10-15 million of Alumetal synergies will be delivered in 2025 [80] - Hydro is targeting an extrusion ingot recycling EBITDA margin of approximately USD 95/tonne in Q3 2025 [72] - Recycling adjusted EBITDA roadmap 2030 potential is NOK ~ 5 - 6 billion [83] Low-Carbon Transition and Sustainability - Hydro is projecting to deliver a CO2 reduction of 15% by year-end 2025 [14] - The company has a target to reduce CO2 emissions by 30% by 2030 [92] - Hydro has secured a new long-term power contract with Hafslund Kraft AS for 3.5 TWh of renewable energy supply from 2031 to 2040 [90]

Chugai's Value Creation & Sustainability - Chugai reorganized its value creation process in 2024, using materiality as axes, aiming to realize advanced and sustainable patient-centric healthcare[9] - The company focuses on creating innovative drugs and services, providing individualized solutions, ensuring quality, and co-creating a healthcare ecosystem[12] - Chugai is implementing materiality by aligning business activities with its materiality story, reflected in management strategies and division activities[14, 16, 20] - A project using the antibody drug discovery support technology MALEXA has advanced to clinical development stage[22, 23] - The company is constructing a disease database for blood coagulation disorders in cooperation with patient associations and academia[29, 35] - Chugai achieved 100% renewable energy ratio in purchased electricity[39] Mid-Size Molecule Drug Platform - Chugai is establishing a pharmaceutical technology platform for mid-size molecule drugs to provide new treatment options[6, 52] - The company is developing a new liquid-phase synthesis method to improve the efficiency of producing mid-size molecules[65] - Through joint research, the cost of certain non-natural amino acids was reduced to less than one third[77] - A 55.5 billion yen investment was made in Fujieda in 2024, 128.8 billion yen in Yokohama in 2022, and 4.5 billion yen in Ukima in 2020[90] Governance and Shareholder Value - Chugai emphasizes dialogue with investors to enhance governance and increase shareholder value[120] - Non-executive directors play a key role in monitoring and advising on management from a global perspective[129] - The company's average annual Total Shareholder Return (TSR) for the past 10 years is 23.5%, compared to 9.5% for TOPIX and 7.8% for TOPIX-17 Pharmaceutical Index[150]

Financial Data and Key Metrics Changes - The company ended the financial year 2025 with a cash and term deposit balance of AUD 129.7 million, providing a cash runway through to the end of calendar year 2026, indicating strong financial management [12][31] - The latest figures for cash and cash equivalents at the end of September 2025 were close to AUD 110 million, reflecting a solid balance sheet [31] Business Line Data and Key Metrics Changes - The lead immuno-oncology candidate, eftilagimod alpha (EFTI), advanced into the TACTI-004 KEYNOTE F59/1 phase III trial in first-line non-small cell lung cancer, with over 170 patients enrolled, surpassing the number needed for a futility analysis [6][40] - The INCITE-003 trial showed a high 62.7% objective response rate and a 90.2% disease control rate across all PD-L1 expression levels, particularly impressive in patients with PD-L1 expression below 50% [9] Market Data and Key Metrics Changes - The company was added to the S&P/ASX 300 Index in September 2024, indicating increased investor confidence and visibility in the market [12][58] - The company continues to face challenges from supply chain disruptions and geopolitical instability, affecting market access and investment flows [13] Company Strategy and Development Direction - The company aims to maintain its leadership in LAG-3 immunotherapy, focusing on clinical trials for EFTI in oncology and autoimmune diseases [5][11] - The strategic collaboration with Merck for the TACTI-004 trial is a critical component of the company's strategy to address high unmet medical needs in first-line non-small cell lung cancer [30][34] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the complex challenges in the biotechnology sector but expressed confidence in navigating these hurdles through strong clinical data and operational skills [12][13] - The company anticipates continued momentum in clinical trials and updates on various studies, including TACTI-004 and APEX-003, in the upcoming financial year [14][59] Other Important Information - The company received positive feedback from the FDA regarding the late-stage clinical development of EFTI in head and neck squamous cell carcinoma patients with low PD-L1 expression [8] - The first-in-human phase I trial of IMP761 showed a promising 80% reduction in T cell activity, supporting its potential in autoimmune diseases [11] Q&A Session Summary Question: Are there copies of the annual report here? - Yes, copies of the annual report are available [16] Question: Any other questions regarding the financial and other reports? - No further questions were submitted regarding the financial and other reports [60]

Financial Data and Key Metrics Changes - The company ended the financial year 2025 with a cash and term deposit balance of AUD 129.7 million, providing a cash runway through to the end of calendar year 2026 [12] - Cash and cash equivalents at the end of September 2025 were close to AUD 110 million, indicating strong cash reserves for research and development [31] Business Line Data and Key Metrics Changes - The lead immuno-oncology candidate, eftilagimod alpha (efti), advanced into the TACTI-004 KEYNOTE F9/1 phase III trial in first-line non-small cell lung cancer, with over 170 patients enrolled [6][36] - The multicenter INSIGHT-003 trial showed a high 62.7% objective response rate and 90.2% disease control rate across all PD-L1 expression levels [9] - The phase II AIPAC-003 trial in metastatic breast cancer completed enrollment, with updates expected at the San Antonio Breast Cancer Symposium in December 2025 [10] Market Data and Key Metrics Changes - The company was added to the S&P/ASX 300 Index in September 2024, reflecting investor confidence in its growth trajectory [12] - The company is conducting trials in 24 countries, with over 100 clinical sites open for enrollment [7][40] Company Strategy and Development Direction - The company aims to develop and commercialize innovative immunotherapies targeting cancer and autoimmune diseases, with a focus on eftilagimod in combination with KEYTRUDA and chemotherapy [14][30] - The strategy includes navigating challenges in the biotechnology sector, such as supply chain disruptions and geopolitical instability, while maintaining a focus on clinical trial execution [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the changing global regulatory environment and emphasized the importance of timely execution of clinical trials [12][13] - The company anticipates meaningful progress in financial year 2026, with continued momentum for TACTI-004 and updates from other trials [14] Other Important Information - The company received positive feedback from the FDA regarding the late-stage clinical development of efti for head and neck cancer patients with low PD-L1 expression [8] - The company was granted 17 new patents across 10 territories for both efti and IMP761 during the financial year 2025 [11] Q&A Session Summary Question: Are there copies of the annual report here? - Yes, copies of the annual report are available [16] Question: Any questions or comments on the management of the company? - No questions were submitted in advance, and no further questions were raised during the meeting [60]